Fast and Efficient Measurement of Clinical and Biological Samples Using Immunoassay-Based Multiplexing Systems.

Immunoassay is one of the most commonly used biomedical techniques to detect the expression of an antibody or an antigen in a test sample. Enzyme-linked immunosorbent assay (ELISA) has been used for a variety of applications including diagnostic tools and quality controls. However, one of the main limitations of ELISA is its lack of multiplexing ability, so ELISA may not be an efficient diagnostic tool when a measurement of multiple determinants is needed for samples with limited quantity such as blood or biological samples from newborns or babies. Although similar to ELISA in assay measurement, multiplex platforms such as bead-based Luminex and multi-array-based MSD (Meso Scale Discovery) are widely used to measure multiple biomarkers from a single analysis. Luminex is a xMAP-based technology that combines several different technologies to provide an efficient and accurate measurement of multiple analytes from a single sample. The multiplexing can be achieved because up to 100 distinct Luminex color-coded microsphere bead sets can be coated with a reagent specific to a particular bioassay, allowing the capture and detection of specific analytes from a sample. Using Multi-array and electrochemiluminescence technologies, the MSD platform provides the multiplex capability with similar consistence as observed in ELISA. Various biological samples that can be analyzed by both Luminex and MSD systems include serum, plasma, tissue and cell lysate, saliva, sputum, and bronchoalveolar Lavage (BAL). The most common Luminex and MSD-based assays are to detect a combined set of cytokines to provide a measurement of cytokine expression profiling for a diagnostic purpose.

[1]  Meenu Wadhwa,et al.  Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell based electrochemiluminescence assay. , 2010, Cytokine.

[2]  Z. Duan,et al.  [Application of Luminex xMAP technology in infectious diseases]. , 2010, Bing du xue bao = Chinese journal of virology.

[3]  Janet S. Lee,et al.  The Influence of Radiographic Phenotype and Smoking Status on Peripheral Blood Biomarker Patterns in Chronic Obstructive Pulmonary Disease , 2009, PloS one.

[4]  F A Cucinotta,et al.  Simultaneous measurement of multiple radiation-induced protein expression profiles using the Luminex(TM) system. , 2004, Advances in space research : the official journal of the Committee on Space Research.

[5]  A. Voller,et al.  ELISA techniques in virology. , 1982, Laboratory and research methods in biology and medicine.

[6]  S. Santulli-Marotto,et al.  Discovering Molecules That Regulate Efferocytosis Using Primary Human Macrophages and High Content Imaging , 2015, PloS one.

[7]  N. Yoshihara.  [ELISA for diagnosis of infections by viruses]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.

[8]  T. Kirchner,et al.  Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody , 2018, Molecular metabolism.

[9]  P. Wadhwa,et al.  Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. , 2005, Journal of reproductive immunology.

[10]  Peterson Em.  ELISA: a tool for the clinical microbiologist. , 1981 .

[11]  J. Lunney,et al.  Development of an 8-plex Luminex assay to detect swine cytokines for vaccine development: assessment of immunity after porcine reproductive and respiratory syndrome virus (PRRSV) vaccination. , 2010, Vaccine.

[12]  F. Sciurba,et al.  Decreased serum TRAIL is associated with increased mortality in smokers with comorbid emphysema and coronary artery disease. , 2018, Respiratory medicine.

[13]  S. Dunbar,et al.  Application of the luminex LabMAP in rapid screening for mutations in the cystic fibrosis transmembrane conductance regulator gene: A pilot study , 2000, Clinical chemistry.

[14]  A multiplex immunoassay for the non-invasive detection of bladder cancer , 2016, Journal of Translational Medicine.

[15]  F. Sciurba,et al.  Plasma Inflammatory Mediators Associated with Bone Metabolism in COPD , 2010, COPD.

[16]  M. Opp,et al.  Lipopolysaccharide-induced increases in cytokines in discrete mouse brain regions are detectable using Luminex xMAP® technology , 2008, Journal of Neuroscience Methods.

[17]  J. Beck,et al.  Enzyme immunoassays with special reference to ELISA techniques. , 1978, Journal of clinical pathology.

[18]  M. Rewers,et al.  A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease. , 2016, Journal of immunological methods.

[19]  G. Salen,et al.  PREVENTION OF CHENODEOXYCHOLIC-ACID TOXICITY WITH LINCOMYCIN , 1975, The Lancet.

[20]  Gerhard Walzl,et al.  An Evaluation of Commercial Fluorescent Bead-Based Luminex Cytokine Assays , 2008, PloS one.

[21]  C. Shriver,et al.  Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. , 2007, Oncology reports.

[22]  C. Foy,et al.  Improved detection of cell surface proteins using an electrochemiluminescent cell-binding assay. , 2010, Journal of immunological methods.

[23]  Yanmei Lu,et al.  Electrochemiluminescence to detect surface proteins on live cells. , 2007, Current opinion in pharmacology.

[24]  E. Engvall,et al.  Quantitative enzyme immunoassay (ELISA) in microbiology. , 1977, Medical biology.

[25]  P. Kleiblova,et al.  Changes of endocrine function of adipose tissue in anorexia nervosa: comparison of circulating levels versus subcutaneous mRNA expression , 2007, Clinical endocrinology.

[26]  D. Peritt,et al.  A novel monoclonal antibody screening method using the Luminex-100 microsphere system. , 2002, Journal of immunological methods.

[27]  S. Robson,et al.  Comparison of three multiplex cytokine analysis systems: Luminex, SearchLight and FAST Quant. , 2006, Journal of immunological methods.

[28]  J. Metcalf,et al.  Gene expression profiling of human alveolar macrophages infected by B. anthracis spores demonstrates TNF-α and NF-κb are key components of the innate immune response to the pathogen , 2009, BMC infectious diseases.

[29]  Weimin Sun,et al.  Technical validation of a TM Biosciences Luminex-based multiplex assay for detecting the American College of Medical Genetics recommended cystic fibrosis mutation panel. , 2006, The Journal of molecular diagnostics : JMD.

[30]  K. Gibney,et al.  GLOVE POWDER AND HIV ELISA TESTS , 1989, The Lancet.

[31]  J. Leader,et al.  Mediastinal and Subcutaneous Chest Fat Are Differentially Associated with Emphysema Progression and Clinical Outcomes in Smokers , 2017, Respiration.

[32]  Naftali Kaminski,et al.  MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis , 2008, PLoS medicine.

[33]  B. Simon,et al.  Sphingosine 1-phosphate rescues canine LPS-induced acute lung injury and alters systemic inflammatory cytokine production in vivo. , 2008, Translational research : the journal of laboratory and clinical medicine.

[34]  C. Ballantyne,et al.  Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. , 2005, Clinical chemistry.

[35]  Jessica M. McMurray,et al.  Inverse association of plasma IL-13 and inflammatory chemokines with lung function impairment in stable COPD: a cross-sectional cohort study , 2007, Respiratory research.

[36]  D. Gaudet,et al.  Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology , 2010, BMC Medical Genetics.

[37]  G. Cockrell,et al.  Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex® Multiplex technology , 2005, Clinical chemistry and laboratory medicine.

[38]  C. Daly,et al.  FALSE-POSITIVE RESULTS WITH HIV ELISA KITS , 1986, The Lancet.

[39]  G. Russ,et al.  Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. , 2009, Human immunology.

[40]  S. Sardy,et al.  BARD1 serum autoantibodies for the detection of lung cancer , 2017, PloS one.

[41]  A. Cesbron-Gautier,et al.  [Luminex technology for HLA typing by PCR-SSO and identification of HLA antibody specificities]. , 2004, Annales de biologie clinique.

[42]  S. Perera,et al.  Radiographic Emphysema, Circulating Bone Biomarkers, and Progressive Bone Mineral Density Loss in Smokers , 2018, Annals of the American Thoracic Society.

[43]  J. Carulli,et al.  Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis , 2013, PloS one.

[44]  B. Teicher,et al.  Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology , 2003, Cancer Chemotherapy and Pharmacology.

[45]  A. Cesbron-Gautier,et al.  Technologie Luminex : application aux typages HLA par biologie moléculaire (PCR‐SSO) et à l‘identification des anticorps anti‐HLA , 2004 .

[46]  L. Giavedoni.  Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using luminex technology. , 2005, Journal of immunological methods.

[47]  N. Kaminski,et al.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. , 2012, American journal of respiratory and critical care medicine.